Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
about
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) DefectsThe Treatment of Activated PI3Kδ Syndrome
P2860
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@en
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@nl
type
label
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@en
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@nl
prefLabel
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@en
Discovery of CDZ173 (Leniolisi ...... 3K Delta-Selective Inhibitors.
@nl
P2093
P2860
P1476
Discovery of CDZ173 (Leniolisi ...... I3K Delta-Selective Inhibitors
@en
P2093
Alexander B Smith
Amanda Littlewood-Evans
Christoph Burkhart
Frédéric Zécri
Gabriele Rummel
Gregory J Hollingworth
Joachim Blanz
Nadege Graveleau
Nicolas Soldermann
Nigel G Cooke
P2860
P304
P356
10.1021/ACSMEDCHEMLETT.7B00293
P577
2017-08-25T00:00:00Z